Psilocybin occasioned mystical-type experiences
- PMID: 32573835
- DOI: 10.1002/hup.2742
Psilocybin occasioned mystical-type experiences
Abstract
Objective: Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical-type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long-term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight strengths and weaknesses in current research, generate novel perspectives and discussion, and consider future avenues for research.
Design: This narrative review was designed to summarise and assess the state of research on psilocybin occasioned mystical-type experiences and applications for the treatment of specific psychiatric conditions.
Results: Contemporary methods on the quantification of mystical-type experiences and their acute subjective effects are discussed. Recent studies provide some understanding of the pharmacological actions of psychedelics although the neurological similarities and differences between spontaneous and psychedelic mystical-type experiences are not well described. Applicability to modern clinical settings is assessed. Potential novel therapeutic applications include use in positive psychology interventions in healthy individuals.
Conclusions: Since 2006 significant advancements in understanding the therapeutic potential of psilocybin-assisted psychotherapy have been made; however, more work is required to understand the neuromechanistic processes and applicability in modern clinical settings. Despite promising results in recent studies, funding issues for clinical trials, legal concerns and socio-cultural resistance provide a counterpoint to experimental evidence.
Keywords: Psilocybin; clinical applications; current research; mystical-type experiences; psychotherapy; quantum change.
© The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons Ltd.
Similar articles
-
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.J Psychopharmacol. 2015 Nov;29(11):1182-90. doi: 10.1177/0269881115609019. Epub 2015 Oct 6. J Psychopharmacol. 2015. PMID: 26442957 Free PMC article.
-
Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.J Psychoactive Drugs. 2012 Nov-Dec;44(5):410-7. doi: 10.1080/02791072.2012.736842. J Psychoactive Drugs. 2012. PMID: 23457892
-
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.Int Rev Psychiatry. 2018 Aug;30(4):331-342. doi: 10.1080/09540261.2018.1474185. Epub 2018 Sep 27. Int Rev Psychiatry. 2018. PMID: 30260256 Review.
-
High dose psilocybin is associated with positive subjective effects in healthy volunteers.J Psychopharmacol. 2018 Jul;32(7):770-778. doi: 10.1177/0269881118780713. Epub 2018 Jun 27. J Psychopharmacol. 2018. PMID: 29945469 Free PMC article.
-
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521880 Review.
Cited by
-
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.Sci Rep. 2023 Feb 11;13(1):2466. doi: 10.1038/s41598-023-29763-x. Sci Rep. 2023. PMID: 36774449 Free PMC article.
-
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.ACS Pharmacol Transl Sci. 2021 Mar 5;4(2):424-435. doi: 10.1021/acsptsci.1c00014. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860172 Free PMC article. Review.
-
The Therapeutic Potential of Psilocybin.Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948. Molecules. 2021. PMID: 34063505 Free PMC article. Review.
-
The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting.Pharmacol Rep. 2025 Aug;77(4):1024-1039. doi: 10.1007/s43440-025-00742-5. Epub 2025 Jun 16. Pharmacol Rep. 2025. PMID: 40522607 Free PMC article. Clinical Trial.
-
N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.Hum Psychopharmacol. 2022 May;37(3):e2835. doi: 10.1002/hup.2835. Epub 2022 Feb 17. Hum Psychopharmacol. 2022. PMID: 35175662 Free PMC article. Review.
References
REFERENCES
-
- Barnby, J. M., & Mehta, M. A. (2018). Psilocybin and mental health- Don't lose control. Frontiers in Psychiatry, 9, 1-3.
-
- Barrett, F., Bradstreet, M., Leoutsakos, J., Johnson, M., & Griffiths, R. (2016). The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279-1295.
-
- Barrett, F., Johnson, M., & Griffiths, R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182-1190.
-
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., … Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. Journal of Humanistic Psychology, 57(4), 354-388.
-
- Bogenschutz, M., Forcehimes, A., Pommy, J., Wilcox, C., Barbosa, P., & Strassman, R. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical